Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed.
Belgi
A S
AS
Azeez
M
M
Hoyle
C
C
Williams
R E A
RE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008775:Methylprednisolone / Q000008:administration & dosage; D010392:Pemphigus / Q000188:drug therapy*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D008775:Methylprednisolone